---
title: "Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291454858.md"
description: "Maxim Group analyst Jason McCarthy reiterated a Buy rating on MediciNova with an unchanged $6 price target. The decision is driven by the company's advancing pipeline, including upcoming data from the MN-001 Phase 2 trial for hypertriglyceridemia and NAFLD. Additionally, the MN-166 ALS program's pivotal COMBAT-ALS trial is expected to report results by late 2026, potentially leading to an NDA submission in early 2027. McCarthy views the risk/reward profile as attractive based on these catalysts."
datetime: "2026-07-01T19:35:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291454858.md)
  - [en](https://longbridge.com/en/news/291454858.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291454858.md)
generator: "portal-rs"
---

# Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target

Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Medicinova, retaining the price target of $6.00.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Jason McCarthy has given his Buy rating due to a combination of factors, including MediciNova’s advancing pipeline and approaching catalysts. He points to the completed Phase 2 trial of MN-001 in patients with hypertriglyceridemia, NAFLD, and type 2 diabetes, where upcoming data on liver fat and triglyceride reduction could validate its multi-pathway mechanism and prior signals of lipid improvement.

McCarthy also emphasizes the MN-166 ALS program, with the pivotal COMBAT-ALS Phase 2b/3 trial expected to deliver topline results by year-end 2026, potentially enabling an NDA submission in the first half of 2027. With additional real-world evidence coming from the SEANOBI expanded-access study and supportive prior safety and efficacy data, he views the overall risk/reward as attractive, maintaining his Buy rating and a $6 price target, which remains unchanged.

### Related Stocks

- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)

## Related News & Research

- [08:36 ETChoose Health Launches Most Comprehensive At-Home Liver Function Test with 20+ Biomarkers and Clinical Risk Scores](https://longbridge.com/en/news/297326666.md)
- [Analyst Maintains Buy Rating on Teladoc with Unchanged $10.50 Price Target Amid Strategic Transition and New CFO Appointment](https://longbridge.com/en/news/297585950.md)
- [Berenberg Bank Keeps Their Buy Rating on Euronav (CMBT)](https://longbridge.com/en/news/297603107.md)
- [Jefferies Sticks to Their Buy Rating for VSE (VSEC)](https://longbridge.com/en/news/297676955.md)
- [GitLab Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts](https://longbridge.com/en/news/297605315.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**